Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sänger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nürnberg P, Perner S, Thomas RK.

Sci Transl Med. 2010 Dec 15;2(62):62ra93. doi: 10.1126/scitranslmed.3001451. Erratum in: Sci Transl Med. 2012 Apr 18;4(130):130er2. Sci Transl Med. 2011 Jan 19;3(66):66er2.

2.

A therapeutic target for smoking-associated lung cancer.

Turner NC, Seckl MJ.

Sci Transl Med. 2010 Dec 15;2(62):62ps56. doi: 10.1126/scitranslmed.3001942.

PMID:
21160076
3.

Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.

Kotani H, Ebi H, Kitai H, Nanjo S, Kita K, Huynh TG, Ooi A, Faber AC, Mino-Kenudson M, Yano S.

Oncogene. 2016 Jul 7;35(27):3587-97. doi: 10.1038/onc.2015.426. Epub 2015 Nov 9.

PMID:
26549034
4.

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.

Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y, Liu K, Dong Z, Zhu G, Qian Z, Tang L, Schöttle J, Zhan P, Ji Q, Kilgour E, Smith PD, Brooks AN, Thomas RK, Gavine PR.

Clin Cancer Res. 2012 Dec 15;18(24):6658-67. doi: 10.1158/1078-0432.CCR-12-2694. Epub 2012 Oct 18. Erratum in: Clin Cancer Res. 2013 Jul 1;19(13):3714. Schöttle, Jakob [added].

5.

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE.

Clin Cancer Res. 2014 Jun 15;20(12):3299-309. doi: 10.1158/1078-0432.CCR-13-3060. Epub 2014 Apr 25.

6.

Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.

Lam SK, Leung LL, Li YY, Zheng CY, Ho JC.

Lung Cancer. 2016 Nov;101:111-119. doi: 10.1016/j.lungcan.2016.10.001. Epub 2016 Oct 4.

PMID:
27794399
7.

Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.

Thomas A, Lee JH, Abdullaev Z, Park KS, Pineda M, Saidkhodjaeva L, Miettinen M, Wang Y, Pack SD, Giaccone G.

J Thorac Oncol. 2014 Apr;9(4):567-71. doi: 10.1097/JTO.0000000000000089.

8.

Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.

Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E, Paggen E, Albus K, Schulte W, Ko YD, Schlesinger A, Ansén S, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Huss S, Göke F, Perner S, Hekmat K, Frank KF, Reiser M, Schnell R, Bos M, Mattonet C, Sos M, Stoelben E, Wolf J, Zander T, Buettner R.

Mod Pathol. 2012 Nov;25(11):1473-80. doi: 10.1038/modpathol.2012.102. Epub 2012 Jun 8.

9.

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.

Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE.

Cancer Res. 2015 Oct 15;75(20):4398-406. doi: 10.1158/0008-5472.CAN-15-0509. Epub 2015 Sep 10.

10.

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.

Malchers F, Dietlein F, Schöttle J, Lu X, Nogova L, Albus K, Fernandez-Cuesta L, Heuckmann JM, Gautschi O, Diebold J, Plenker D, Gardizi M, Scheffler M, Bos M, Seidel D, Leenders F, Richters A, Peifer M, Florin A, Mainkar PS, Karre N, Chandrasekhar S, George J, Silling S, Rauh D, Zander T, Ullrich RT, Reinhardt HC, Ringeisen F, Büttner R, Heukamp LC, Wolf J, Thomas RK.

Cancer Discov. 2014 Feb;4(2):246-57. doi: 10.1158/2159-8290.CD-13-0323. Epub 2013 Dec 3.

11.

Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.

Adachi Y, Watanabe K, Kita K, Kitai H, Kotani H, Sato Y, Inase N, Yano S, Ebi H.

Carcinogenesis. 2017 Oct 26;38(11):1063-1072. doi: 10.1093/carcin/bgx091.

PMID:
28968756
12.

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.

Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, Gray NS, Meyerson M.

PLoS One. 2011;6(6):e20351. doi: 10.1371/journal.pone.0020351. Epub 2011 Jun 7.

13.

Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer.

Malchers F, Ercanoglu M, Schütte D, Castiglione R, Tischler V, Michels S, Dahmen I, Brägelmann J, Menon R, Heuckmann JM, George J, Ansén S, Sos ML, Soltermann A, Peifer M, Wolf J, Büttner R, Thomas RK.

Clin Cancer Res. 2017 Sep 15;23(18):5527-5536. doi: 10.1158/1078-0432.CCR-17-0478. Epub 2017 Jun 19.

PMID:
28630215
14.

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.

Rooney C, Geh C, Williams V, Heuckmann JM, Menon R, Schneider P, Al-Kadhimi K, Dymond M, Smith NR, Baker D, French T, Smith PD, Harrington EA, Barrett JC, Kilgour E.

PLoS One. 2016 Feb 23;11(2):e0149628. doi: 10.1371/journal.pone.0149628. eCollection 2016.

15.

High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.

Preusser M, Berghoff AS, Berger W, Ilhan-Mutlu A, Dinhof C, Widhalm G, Dieckmann K, Wöhrer A, Hackl M, von Deimling A, Streubel B, Birner P.

Lung Cancer. 2014 Jan;83(1):83-9. doi: 10.1016/j.lungcan.2013.10.004. Epub 2013 Oct 17.

PMID:
24183471
16.

FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway.

Ji W, Yu Y, Li Z, Wang G, Li F, Xia W, Lu S.

Oncotarget. 2016 Mar 22;7(12):15118-34. doi: 10.18632/oncotarget.7701.

17.

Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.

Tran TN, Selinger CI, Kohonen-Corish MR, McCaughan BC, Kennedy CW, O'Toole SA, Cooper WA.

Lung Cancer. 2013 Sep;81(3):462-7. doi: 10.1016/j.lungcan.2013.05.015. Epub 2013 Jun 24.

PMID:
23806793
18.

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.

Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.

Cancer Sci. 2016 Nov;107(11):1667-1676. doi: 10.1111/cas.13071.

19.

Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.

Göke F, Franzen A, Menon R, Goltz D, Kirsten R, Boehm D, Vogel W, Göke A, Scheble V, Ellinger J, Gerigk U, Fend F, Wagner P, Schroeck A, Perner S.

Chest. 2012 Oct;142(4):1020-1026. doi: 10.1378/chest.11-2943.

PMID:
22499828
20.

FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.

Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, Pan Y, Ye T, Zhang Y, Luo X, Zhang Y, Pan B, Li B, Li H, Zhang J, Pao W, Ji H, Sun Y, Chen H.

Clin Cancer Res. 2014 Aug 1;20(15):4107-14. doi: 10.1158/1078-0432.CCR-14-0284. Epub 2014 May 21.

Supplemental Content

Support Center